Quality of life in refractory ascites: Transjugular intrahepatic portal-systemic shunting versus medical therapy

Hepatology

Volumn 42, Issue 3, 2005, Pages 635-640

  Campbell, Mical S ^a   Brensinger, Colleen M ^a   Sanyal, Arun J ^b   Gennings, Chris ^c   Wong, Florence ^d   Kowdley, Kris V ^e   McCashland, Timothy ^f   Reddy, K Rajender ^a,g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; DIURETIC AGENT; FUROSEMIDE; SPIRONOLACTONE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ARTICLE; ASCITES; BRAIN DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMERGENCY WARD; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPONATREMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARACENTESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME; UREMIA;

ANALYSIS OF VARIANCE; ASCITES; FOLLOW-UP STUDIES; HUMANS; PARACENTESIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 24144484699     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20840     Document Type: Article

References (19)

1. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American study for the treatment of refractory ascites. Gastroenterology 2003;124:634-641.
2. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996; 25:135-144.
3. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Ruiz del Arbol L, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-1847.
4. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701-1707.
5. Salerno F, Merli Manuela M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. HEPATOLOGY 2004;40:629-635.
6. Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001;120:170-178.
7. Arguedas MR, DeLawrence TG, McGuire MB. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003;48:1622-1626.
8. Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of liver disease. Am J Gastroenterol 2001;96:2199-2205.
9. Cordoba J, Flavia M, Jacas C, Sauleda S, Esteban JI, Guardia J. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003;39:231-238.
10. Zhuang ZW, Ten GJ, Jeffery RF, Gemery JM, d'Othee BJ, Bettmann MA. Long-term results and quality of life in patients treated with transjugular intrahepatic portosystemic shunts. AJR Am J Roentgenol 2002;179:1597-1603.
11. Gulberg V, Liss I, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion 2002;66:127-130.
12. Nazarian GK, Ferral H, Bjarnason H, Castaneda-Zuniga WR, Rank JM, Bernadas CA, et al. Effect of transjugular intrahepatic portosystemic shunt on quality of life. AJR Am J Roenteneol 1996;167:963-969.
13. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. HEPATOLOGY 1996;23: 164-176.
14. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute, 1994.
15. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chroni liver disease. Am J Gastroenterol 2001;96:579-583.
16. van der Plas SM, Hansen BE, de Boer JB, Stijnen T, Passchier J, de Man RA, et al. The liver disease symptom index 2.0; validation of a disease-specific questionnaire. Qual Life Res 2004;13:1469-1481.
17. Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA. Clinical Significance Consensus Meeting Group. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clinic Proceedings 2002;77:56l-571.
18. Chong CAKY, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Heath-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-638.
19. Wells CD, Murrill WB, Arguedas MR. Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease. Dig Dis Sci 2004;49: 453-458.